AstraZeneca terminated a Phase 3 lung cancer trial of volrustomig after an interim data check indicated survival targets were unlikely to be met versus an active comparator, according to the company’s latest pipeline update. The stop reflects a common late-stage inflection point: if survival endpoints appear out of reach, programs are rapidly paused. In a separate pipeline move, Evaxion discontinued its next-gen solid tumor vaccine EVX-03 as a portfolio management decision, redirecting resources toward an ongoing brain-cancer program. The company said learnings from EVX-03 were applied to EVX-05 and EVX-04, with EVX-05 developed in collaboration with Duke University for glioblastoma using ERV-derived targets. Both actions highlight how sponsors reallocate capital away from weaker clinical probabilities and toward programs with clearer mechanistic differentiation or stronger translational focus.